Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

GGHCX vs. QAAGZX: which is better?

Bottom line

GGHCX vs QAAGZX: the short answer

GGHCX (INVESCO Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 57% by weight.

But QAAGZX is far broader, holding 277 positions to 82 for GGHCX, so beyond the top names it adds exposure GGHCX doesn't have.

QAAGZX is cheaper at 0.86% vs 1.07% — a difference of $21 a year per $10,000 invested.

Over five years, QAAGZX returned +4.1% a year vs +2.6% for GGHCX.

GGHCX has a front-end sales load of up to 5.5%; the other does not.

Updated Nov 19, 2026

GGHCX vs QAAGZX side by side

GGHCXQAAGZX
TypeMutual fundETF
Fund familyInvescoT. Rowe Price
CategoryHealth Care SectorHealth Care Sector
Expense ratio1.07%0.86%
Annual cost per $10k$107$86
10-yr cost on $10k (prospectus)$1,784$1,061
Max front load5.5%None
12b-1 fee0.25%0%
1-yr return+9.2%+18.1%
5-yr return (annualized)+2.6%+4.1%
10-yr return (annualized)+5.8%+9.0%
Best quarter+19.6%+23.4%
Worst quarter−16.5%−15.8%
Net assets (fund)$1.2B$751.7M
Number of holdings82277
Portfolio turnover59%65%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearGGHCXQAAGZXDifference
2025+15.5%+18.1%−2.6%
2024+4.0%+1.7%+2.3%
2023+3.1%+3.0%+0.1%
2022−13.5%−12.5%−1.1%
2021+12.2%+13.1%−0.9%
2020+14.5%+29.6%−15.2%
2019+32.0%+29.0%+3.1%
2018+0.5%+1.1%−0.7%
2017+15.5%+27.6%−12.1%
2016−11.7%−10.5%−1.2%

Source: Fund prospectus bar charts

Holdings overlap

11 of GGHCX's top 25 holdings also appear in QAAGZX's top 25.

Shared top holdings
HoldingGGHCXQAAGZX
Eli Lilly and Co.10.59%14.06%
Johnson & Johnson6.76%6.64%
UnitedHealth Group Inc.6.17%5.88%
Merck & Co., Inc.4.59%4.00%
AbbVie Inc.4.03%5.12%
Gilead Sciences, Inc.3.63%2.79%
CVS Health Corp.2.52%0.93%
Cardinal Health, Inc.2.10%1.04%
Guardant Health, Inc.2.04%1.22%
Vertex Pharmaceuticals Inc.2.01%2.26%
Thermo Fisher Scientific Inc.1.55%2.53%

Source: SEC Form N-PORT

GGHCX top 10

  1. Eli Lilly and Co. — 10.59%
  2. Johnson & Johnson — 6.76%
  3. UnitedHealth Group Inc. — 6.17%
  4. Invesco Private Prime Fund — 4.67%
  5. Merck & Co., Inc. — 4.59%
  6. AbbVie Inc. — 4.03%
  7. Gilead Sciences, Inc. — 3.63%
  8. argenx SE — 3.24%
  9. CVS Health Corp. — 2.52%
  10. Welltower Inc. — 2.34%

QAAGZX top 10

  1. Eli Lilly & Co — 14.06%
  2. Johnson & Johnson — 6.64%
  3. Unitedhealth Group Inc — 5.88%
  4. Abbvie Inc — 5.12%
  5. Merck & Co. Inc. — 4.00%
  6. Gilead Sciences Inc — 2.79%
  7. Thermo Fisher Scientific Inc — 2.53%
  8. Vertex Pharmaceuticals Inc — 2.26%
  9. Bristol-myers Squibb Co — 2.12%
  10. Abbott Laboratories — 1.91%

FAQ

What is the difference between GGHCX and QAAGZX?
GGHCX (INVESCO Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 57% by weight. But QAAGZX is far broader, holding 277 positions to 82 for GGHCX, so beyond the top names it adds exposure GGHCX doesn't have.
Which is cheaper, GGHCX or QAAGZX?
QAAGZX has the lower expense ratio (0.86%).
Should I own both GGHCX and QAAGZX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.